Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is well positioned within the evolving field of Wnt therapeutics, with its dual Wnt/ anti-VEGF antibody SZN-8141 entering the clinic in DME patients by the end of 3Q26 for the treatment of retinal vascular diseases. With a successful trial outcome, the company could potentially see an initial data catalyst in 2H27. Additionally, Surrozen's recent update from the US Patent Trial and Appeal Board (PTAB) denying the institution of a post-grant review petition reinforces the company's intellectual property position. The company reported strong Q2 2026 financials, with a net gain of $50.2M and $102.0M in cash and equivalents. With a diverse pipeline and promising preclinical data, Surrozen is poised for success in the treatment of retinal diseases.

Bears say

Surrozen is currently in the clinical-stage of development of its Wnt pathway modulating drugs, and while they have upcoming milestones such as IND submission and initiation of a Phase 1b/2a trial, the market will be looking for initial evidence of safety, tolerability, and clinical activity. With traditional anti-VEGF wet AMD treatments having shown improvements in durability, Surrozen's potential for improved efficacy, longer-lasting results, and reduced injection frequency is promising. However, there are significant risks involved in the success of their developmental candidates and their ability to secure funding for operations.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.